FOR IMMEDIATE RELEASE
- Major expansion of ISSCA’s peptide education program includes updated modules, practical resources, and two new physician reference books
- Program addresses dosing frameworks, combination strategies, preparation, and protocol development within applicable medical and regulatory frameworks
- Peptide Certification 2.0 builds on ISSCA’s existing physician education infrastructure
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced Peptide Certification 2.0, a major expansion of its peptide medicine education and certification program.
The updated program includes expanded curriculum modules, updated educational materials, practical physician resources, and two new specialized peptide reference guides addressing dosing frameworks, combination strategies, preparation, and protocol development within applicable medical and regulatory frameworks.
ISSCA positioned Peptide Certification 2.0 as a comprehensive physician-focused educational resource, building on the organization’s existing peptide certification track offered at its conference programming across Latin America, the Middle East, and other regions.
“Peptide medicine has moved fast, and the education has to keep pace with it,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Version 2.0 gives physicians a genuinely updated curriculum and two reference resources they can use in daily practice.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
